Skip to main content
. Author manuscript; available in PMC: 2019 Sep 1.
Published in final edited form as: Urol Pract. 2018 Sep;5(5):351–359. doi: 10.1016/j.urpr.2017.07.004

Figure 4.

Figure 4.

Cost comparisons between provider types for OAB medications. Most significant source of potential savings by far across both types of providers was solifenacin. Other significant sources included mirabegron and fesoterodine. Tolterodine ER generated significant potential savings among nonurologists due to increased use (p <0.01).